ALIROCUMAB (Praluent®)

Clinical Indication

Adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels


Not yet reviewed

Date of classification

March 2020


Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.